Results from a Phase II trial of a cholestoral drug from Regeneron (REGN +0.7%
) were good but were upstaged
at a heart conference by the outcome of a Phase I trial of a rival treatment from Amgen (AMGN +1.5%
), which was better. Still, both drugs have a long way to go before they'll be able to enter a market that could be worth $20B/year.